Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.37 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25006980 | 0.70 | POLB (0.35) | CES1HPGDALDH1A1HSD17B10TSHR | |
| SCHEMBL20904792 | 0.69 | PLOD2 (0.45) | CES1HPGDALDH1A1HSD17B10TSHR | |
| SCHEMBL6840487 | 0.68 | PLA2G4A (0.50) | PLA2G4AHSD17B3ALDH1A1HSD17B10LMNA | |
| Bromide SCHEMBL6329679 | 0.68 | PLA2G4A (0.56) | CES1PLA2G4AHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL20429003 | 0.67 | PLA2G4A (0.49) | PLA2G4AHSD17B3HPGDALDH1A1HSD17B10 | |
| SCHEMBL4828394 | 0.67 | SMN1; SMN2 (0.45) | CES1HSD17B3ALDH1A1TSHRRECQL | |
| SCHEMBL4461679 | 0.65 | HSD17B3 (0.33) | CES1PLA2G4AHSD17B3HPGDALDH1A1 | |
| SCHEMBL12101028 | 0.65 | PLA2G4A (0.47) | PLA2G4AHSD17B3HPGDALDH1A1HSD17B10 | |
| SCHEMBL26254903 | 0.64 | HSD17B3 (0.48) | CES1HSD17B3HPGDALDH1A1HSD17B10 | |
| SCHEMBL8254736 | 0.64 | PKM (0.58) | HSD17B3HPGDALDH1A1HSD17B10ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604025-B2 | Heterocyclic sulfonamides | CYTOKINETICS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-7595322-B2 | Heterocyclic sulfonamides as modulators of cardiac sarcomeres | CYTOKINETICS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-20070078126-A1 | Useful in selective modulation of cardiac sarcomere, for example, by potentiating cardiac myosin; can be used to treat heart failure including CHF, particularly systolic heart failure; 4-[4-chloro-3-(5-phenyl-[1,3,4]thiadiazol-2-ylcarbamoyl)-benzenesulfonyl]-piperazine-1-carboxylic acid ethyl ester | CYTOKINETICS, INCORPORATED | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078126-A1 | Useful in selective modulation of cardiac sarcomere, for example, by potentiating cardiac myosin; can be used to treat heart failure including CHF, particularly systolic heart failure; 4-[4-chloro-3-(5-phenyl-[1,3,4]thiadiazol-2-ylcarbamoyl)-benzenesulfonyl]-piperazine-1-carboxylic acid ethyl ester | MYLK2, MYH2, MYH14 | CES1 2725/4885PLA2G4A 1162/4885HSD17B3 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.